Specializing in Blood Disorder & Cancer Care MENU 925.939.9610 FAQS WHAT IF I HAVE TO CANCEL AN APPOINTMENT? » WHAT IS CONTRA COSTA ONCOLOGY’S PRIVACY POLICY? » CAN FAMILY MEMBERS ATTEND MY APPOINTMENTS? » CAN FAMILY MEMBERS RECEIVE INFORMATION ABOUT MY CARE? » WHAT ITEMS WILL I NEED FOR MY APPOINTMENT? » WHAT INFORMATION WILL I NEED TO PROVIDE TO YOUR OFFICE WHEN I CHECK IN? » WHERE CAN I FIND DIRECTIONS TO YOUR OFFICE? » HOW LONG WILL MY APPOINTMENT LAST? » WHAT ARE THE OFFICE HOURS? » WHAT IF I NEED MEDICAL ATTENTION PRIOR TO MY SCHEDULED VISIT? » WHAT IF I EXPERIENCE A PROBLEM AFTER HOURS, OR ON A WEEKEND OR HOLIDAY? » WHAT IF I HAVE A LIFE-THREATENING EMERGENCY? » WHAT IS CONTRA COSTA ONCOLOGY’S FINANCIAL POLICY? » HOW DO I ACQUIRE AN AUTHORIZATION? » WHAT FOREIGN LANGUAGES ARE SPOKEN IN THE OFFICE? » WALNUT CREEK DANVILLE ROSSMOOR PHONE 925.939.9610 FAX 925.939.9630 CONTRA COSTA ONCOLOGY ALL RIGHTS RESERVED © WEBSITE BY THE MARCOM GROUP

Specializing in Blood Disorder & Cancer Care MENU 925.939.9610 IMLYGIC® Alongside other prominent Bay Area medical centers like St. Mary’s SF and Stanford Medical Center, Contra Costa Oncology is now offering IMLYGIC for local treatment of melanoma that is recurrent after initial surgery. Contra Costa Oncology is currently the only medical center in the East Bay patients can receive this therapy. Please speak with your physician to see if IMLYGIC is a fit for you. ABOUT IMLYGIC® (TALIMOGENE LAHERPAREPVEC) IMLYGIC® (talimogene laherparepvec) is a genetically modified herpes simplex type 1 virus that is injected directly into tumors. IMLYGIC replicates inside tumor cells and produces GM-CSF, an immunostimulatory protein. IMLYGIC then causes the cell to rupture and die in a process called lysis. The rupture of the cancer cells causes the release of tumor-derived antigens, which together with virally derived GM-CSF may help to promote an anti-tumor immune response. However, the exact mechanism of action is unknown. IMLYGIC is the first oncolytic viral therapy approved by the U.S. Food and Drug Administration (FDA) based on therapeutic benefit demonstrated in a pivotal study. IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. IMLYGIC has not been shown to improve OS or have an effect on visceral metastases. For additional information, please speak with your physician and visit the IMLYGIC website. WALNUT CREEK DANVILLE ROSSMOOR PHONE 925.939.9610 FAX 925.939.9630 CONTRA COSTA ONCOLOGY ALL RIGHTS RESERVED © WEBSITE BY THE MARCOM GROUP